AIとがん研究 ── AML ── 2026-11-16
AML 1 本。筆頭: Development and validation of a machine learning model to predict the daily risk of febrile neutropenia in patients with AML undergoing chemotherapy
急性骨髄性白血病(AML)の治療・治験とAI
- Development and validation of a machine learning model to predict the daily risk of febrile neutropenia in patients with AML undergoing chemotherapy抄録(全訳)掲載誌の IF 相当:8.1(OpenAlex の直近 2 年の平均被引用数・2026-11-13 時点の値、2026-11-15 に取得。正式な IF(Clarivate)ではない)書誌:Mervaala-Muroke A, Toivanen L, Ettala P, Räty R, Keränen M, Brück O. Development and validation of a machine learning model to predict the daily risk of febrile neutropenia in patients with AML undergoing chemotherapy. Commun Med. 2026 Nov 13 [Epub ahead of print]. doi:10.1038/s43856-026-02001-x.確認の範囲:抄録のみ確認